Welcome to our dedicated page for Atea Pharmaceuticals news (Ticker: AVIR), a resource for investors and traders seeking the latest updates and insights on Atea Pharmaceuticals stock.
Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, dedicated to discovering, developing, and commercializing oral antiviral therapies aimed at treating severe viral diseases. Founded in 2012, Atea focuses on addressing unmet medical needs, particularly in serious viral infections caused by single-stranded RNA viruses.
The company's leading product candidate is AT-527 (bemnifosbuvir), an antiviral agent developed for treating COVID-19, caused by the SARS-CoV-2 virus. Currently, AT-527 is undergoing Phase 3 clinical trials. Additionally, the combination of bemnifosbuvir and ruzasvir, an oral NS5A inhibitor, is being developed for treating Hepatitis C Virus (HCV) and has shown promising results in Phase 2 trials. This combination therapy aims to provide a highly potent pan-genotypic antiviral treatment with a short treatment duration and fewer contraindications, particularly beneficial for HCV patients.
Beyond COVID-19 and HCV, Atea is also advancing other antiviral therapies in its pipeline, including AT-787 for Hepatitis C (under Phase 2 clinical trial), AT-752 for Dengue (under Phase 2 trial), and other candidates like AT-889 and AT-934 for Respiratory Syncytial Virus (currently under clinical trials).
Recent achievements include positive initial data from a Phase 2 study of bemnifosbuvir and ruzasvir for HCV, showing a 97% sustained virologic response rate at 12 weeks post-treatment. Furthermore, Atea has completed enrollment for the Phase 3 SUNRISE-3 trial for treating high-risk COVID-19 patients, with results expected in the second half of 2024.
Financially, Atea reported a solid cash position of $578.1 million as of December 31, 2023, enabling them to continue advancing their clinical programs. Collaborations and strategic partnerships play a crucial role in Atea’s progress, helping to broaden its scope and enhance its therapeutic offerings.
Investors and stakeholders can stay informed about Atea’s developments through their regular updates, financial reports, and participation in industry conferences. For more information, visit their official website at www.ateapharma.com.
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) has announced upcoming presentations at the ISIRV-WHO virtual conference, taking place from October 19 to 21, 2021. The company will present analyses and interim results from the AT-527 COVID-19 clinical trial program, focusing on a Phase 2 study involving high-risk hospitalized patients and findings from a bronchoalveolar lavage study in healthy volunteers. Atea is collaborating with Roche to advance AT-527 as an oral antiviral treatment for COVID-19, aiming to provide a critical at-home treatment option as the virus becomes endemic.
Atea Pharmaceuticals (Nasdaq: AVIR) announced that CEO Jean-Pierre Sommadossi will participate in a fireside chat at the Guggenheim 2nd Annual Vaccines & Infectious Day Conference on October 5, 2021, at 9:30 a.m. ET. A live webcast will be available on the company's website for 90 days post-event. Atea focuses on developing oral therapies for life-threatening viral infections, including SARS-CoV-2, dengue virus, HCV, and RSV, utilizing its proprietary nucleotide prodrug platform to address unmet medical needs.
Atea Pharmaceuticals announced participation in the Morgan Stanley 19th Annual Global Healthcare Conference on September 14, 2021, at 2:00 p.m. ET. CEO Jean-Pierre Sommadossi and the management team will engage in a fireside chat. A live webcast will be accessible on Atea's website, with a replay available for 90 days post-event. Atea focuses on developing oral therapies for severe viral diseases, leveraging its proprietary nucleotide prodrug platform to target viruses like SARS-CoV-2 and HCV.
Atea Pharmaceuticals (AVIR) announced promising data for its dengue virus treatment candidate, AT-752, published in Antimicrobial Agents and Chemotherapy. The research shows AT-752 has potent in vitro and in vivo activity against multiple dengue virus serotypes, reducing viremia and improving survival rates in animal models. The Phase 1a clinical trial demonstrated good tolerance with no serious adverse events at doses up to 1500 mg. Dengue fever is a significant global health issue, with 400 million infections annually, highlighting the urgency for effective antiviral treatments.
Atea Pharmaceuticals (AVIR) announced promising interim Phase 2 results for AT-527, a COVID-19 treatment, showing rapid viral load decrease in hospitalized patients. The active metabolite achieved target antiviral levels in lung fluid, critical for effective treatment. Collaboration with Roche continues, facilitating multiple ongoing clinical studies. Financially, Q2 2021 collaboration revenue reached $60.4 million, with a net income of $1.5 million, significantly improving from a loss in the previous year. Cash reserves stand at $816.5 million, reflecting strong financial backing for ongoing development.
Atea Pharmaceuticals (Nasdaq: AVIR) announced a live conference call and audio webcast on August 12, 2021, at 4:30 p.m. ET to discuss its second-quarter financial results and provide a clinical update. The call can be accessed via phone or through the company's website. Atea focuses on developing oral therapeutics for severe viral infections, utilizing a proprietary nucleotide prodrug platform for treating viruses such as SARS-CoV-2, HCV, and RSV. For more information, visit Atea Pharmaceuticals.
Atea Pharmaceuticals (Nasdaq: AVIR) announced that CEO Jean-Pierre Sommadossi and the management team will participate in a fireside chat at the William Blair Biotech Focus Conference on July 15, 2021, at 12:00 p.m. ET. A live webcast will be available on Atea's website, with a replay accessible for 90 days post-event.
Atea is a clinical-stage biopharmaceutical company focused on developing oral therapeutics for severe viral infections, including COVID-19, using its proprietary nucleotide prodrug platform.
Atea Pharmaceuticals announced promising interim results from its global Phase 2 study of AT-527, an oral antiviral for COVID-19, showing significant viral load reductions in hospitalized patients. In 70 high-risk patients, those receiving AT-527 exhibited an 80% greater mean reduction in viral load by Day 2 compared to placebo. Clearance of SARS-CoV-2 was observed in 47% of patients by Day 14. AT-527 demonstrated a favorable safety profile with no drug-related serious adverse events. Ongoing trials include Phase 2 MOONSONG and Phase 3 MORNINGSKY, with more results expected in 2021.
Atea Pharmaceuticals (Nasdaq: AVIR) has achieved a significant milestone by securing a $50 million payment under its license agreement with Roche for the development of AT-527, an oral antiviral for COVID-19. This payment reflects the ongoing collaboration and progress in clinical trials, including the global Phase 3 MORNINGSKY trial. Atea retains commercialization rights in the U.S., while Roche holds them outside the U.S. AT-527 is designed to minimize viral replication and could be used in both pre- and post-exposure prophylactic settings.
Atea Pharmaceuticals has appointed Claudio Avila, MB, BS, Ph.D., as Senior Vice President of Medical Affairs. Previously at Gilead Sciences, Dr. Avila brings significant experience in medical affairs focusing on COVID-19 and other viral diseases. CEO Jean-Pierre Sommadossi expressed confidence in Dr. Avila’s expertise to enhance Atea’s capabilities, particularly in advancing its antiviral pipeline, including AT-527 for COVID-19. Atea aims to develop innovative oral therapeutics for severe viral infections, leveraging its proprietary nucleotide prodrug platform.
FAQ
What is the current stock price of Atea Pharmaceuticals (AVIR)?
What is the market cap of Atea Pharmaceuticals (AVIR)?
What is Atea Pharmaceuticals, Inc.?
What are the main products developed by Atea Pharmaceuticals?
What is the status of the AT-527 (bemnifosbuvir) clinical trials?
What recent achievements has Atea Pharmaceuticals made?
Where is Atea Pharmaceuticals headquartered?
How does Atea Pharmaceuticals plan to address unmet medical needs?
What is the financial condition of Atea Pharmaceuticals?
How can I get more information about Atea Pharmaceuticals?
What are the expected upcoming events for Atea Pharmaceuticals?
Who should be interested in Atea Pharmaceuticals’ updates?
